Doxazosin
| Clinical data | |
|---|---|
| Pronunciation | /dɒkˈseɪzəsɪn/ dok-SAY-zə-sin OR /ˌdɒksəˈzoʊsɪn/ DOK-sə-ZOH-sin |
| Trade names | Cardura, Carduran, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a693045 |
| License data | |
| Routes of administration | By mouth |
| Drug class | α1 blocker |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 65% |
| Protein binding | 98% |
| Metabolism | Liver |
| Elimination half-life | 22 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.128.642 |
| Chemical and physical data | |
| Formula | C23H25N5O5 |
| Molar mass | 451.483 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.
Common side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective α1-adrenergic blocker in the quinazoline class of compounds.
Doxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.